ID   P3C2A_HUMAN             Reviewed;        1686 AA.
AC   O00443; B0LPH2; B4E2G4; Q14CQ9;
DT   30-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   10-JUL-2007, sequence version 2.
DT   10-MAY-2017, entry version 160.
DE   RecName: Full=Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha;
DE            Short=PI3K-C2-alpha;
DE            Short=PtdIns-3-kinase C2 subunit alpha;
DE            EC=2.7.1.154;
DE   AltName: Full=Phosphoinositide 3-kinase-C2-alpha;
GN   Name=PIK3C2A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, COFACTOR, ENZYME
RP   REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.
RX   PubMed=9337861; DOI=10.1042/bj3260139;
RA   Domin J., Pages F., Volinia S., Rittenhouse S.E., Zvelebil M.J.,
RA   Stein R.C., Waterfield M.D.;
RT   "Cloning of a human phosphoinositide 3-kinase with a C2 domain which
RT   displays reduced sensitivity to the inhibitor wortmannin.";
RL   Biochem. J. 326:139-147(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION, ENZYME REGULATION, AND SUBCELLULAR LOCATION.
RX   PubMed=10766823; DOI=10.1074/jbc.275.16.11943;
RA   Domin J., Gaidarov I., Smith M.E.K., Keen J.H., Waterfield M.D.;
RT   "The class II phosphoinositide 3-kinase PI3K-C2alpha is concentrated
RT   in the trans-Golgi network and present in clathrin-coated vesicles.";
RL   J. Biol. Chem. 275:11943-11950(2000).
RN   [8]
RP   FUNCTION, COFACTOR, AND IDENTIFICATION IN A COMPLEX WITH ERBB2 AND
RP   EGFR.
RX   PubMed=10805725; DOI=10.1128/MCB.20.11.3817-3830.2000;
RA   Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D.,
RA   Domin J.;
RT   "Class II phosphoinositide 3-kinases are downstream targets of
RT   activated polypeptide growth factor receptors.";
RL   Mol. Cell. Biol. 20:3817-3830(2000).
RN   [9]
RP   SUBCELLULAR LOCATION, NUCLEAR LOCALIZATION SIGNAL, PHOSPHORYLATION,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=11606566; DOI=10.1074/jbc.M104610200;
RA   Didichenko S.A., Thelen M.;
RT   "Phosphatidylinositol 3-kinase c2alpha contains a nuclear localization
RT   sequence and associates with nuclear speckles.";
RL   J. Biol. Chem. 276:48135-48142(2001).
RN   [10]
RP   FUNCTION, ENZYME REGULATION, SUBCELLULAR LOCATION, INTERACTION WITH
RP   CLATHRIN, AND MUTAGENESIS OF 103-LEU--ASP-107.
RX   PubMed=11239472; DOI=10.1016/S1097-2765(01)00191-5;
RA   Gaidarov I., Smith M.E.K., Domin J., Keen J.H.;
RT   "The class II phosphoinositide 3-kinase C2alpha is activated by
RT   clathrin and regulates clathrin-mediated membrane trafficking.";
RL   Mol. Cell 7:443-449(2001).
RN   [11]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=14563213; DOI=10.1186/1472-6890-3-4;
RA   El Sheikh S.S., Domin J., Tomtitchong P., Abel P., Stamp G.,
RA   Lalani E.-N.;
RT   "Topographical expression of class IA and class II phosphoinositide 3-
RT   kinase enzymes in normal human tissues is consistent with a role in
RT   differentiation.";
RL   BMC Clin. Pathol. 3:4-4(2003).
RN   [12]
RP   FUNCTION, PHOSPHORYLATION AT SER-259, MUTAGENESIS OF SER-254; SER-259;
RP   SER-262 AND SER-266, LACK OF PHOSPHORYLATION AT SER-244; SER-249;
RP   SER-251; SER-254; SER-262 AND SER-266, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=12719431; DOI=10.1074/jbc.M301657200;
RA   Didichenko S.A., Fragoso C.M., Thelen M.;
RT   "Mitotic and stress-induced phosphorylation of HsPI3K-C2alpha targets
RT   the protein for degradation.";
RL   J. Biol. Chem. 278:26055-26064(2003).
RN   [13]
RP   FUNCTION IN ASSEMBLY AND CELLULAR DISTRIBUTION OF CLATHRIN,
RP   INTERACTION WITH CLATHRIN, MUTAGENESIS OF ASP-1250, AND REGION.
RX   PubMed=16215232; DOI=10.1074/jbc.M507731200;
RA   Gaidarov I., Zhao Y., Keen J.H.;
RT   "Individual phosphoinositide 3-kinase C2alpha domain activities
RT   independently regulate clathrin function.";
RL   J. Biol. Chem. 280:40766-40772(2005).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-108 AND SER-259, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-60; SER-108; SER-259 AND
RP   SER-338, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-259, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-259, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   FUNCTION IN DYNAMIN-INDEPENDENT ENDOCYTOSIS.
RX   PubMed=21081650; DOI=10.1242/jcs.071712;
RA   Krag C., Malmberg E.K., Salcini A.E.;
RT   "PI3KC2alpha, a class II PI3K, is required for dynamin-independent
RT   internalization pathways.";
RL   J. Cell Sci. 123:4240-4250(2010).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-108 AND SER-259, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   TISSUE SPECIFICITY.
RX   PubMed=21127054; DOI=10.1074/jbc.M110.200295;
RA   Dominguez V., Raimondi C., Somanath S., Bugliani M., Loder M.K.,
RA   Edling C.E., Divecha N., da Silva-Xavier G., Marselli L.,
RA   Persaud S.J., Turner M.D., Rutter G.A., Marchetti P., Falasca M.,
RA   Maffucci T.;
RT   "Class II phosphoinositide 3-kinase regulates exocytosis of insulin
RT   granules in pancreatic beta cells.";
RL   J. Biol. Chem. 286:4216-4225(2011).
RN   [23]
RP   REVIEW ON FUNCTION.
RX   PubMed=17371240; DOI=10.1042/BST0350229;
RA   Falasca M., Maffucci T.;
RT   "Role of class II phosphoinositide 3-kinase in cell signalling.";
RL   Biochem. Soc. Trans. 35:211-214(2007).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-259 AND SER-327, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-108; SER-259; SER-327;
RP   SER-630; SER-1281 AND SER-1553, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-259, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 1405-1544, PHOSPHOINOSITIDE
RP   BINDING, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ARG-1488; VAL-1490;
RP   LEU-1491; ARG-1493 AND ARG-1503.
RX   PubMed=17038310; DOI=10.1074/jbc.M607079200;
RA   Stahelin R.V., Karathanassis D., Bruzik K.S., Waterfield M.D.,
RA   Bravo J., Williams R.L., Cho W.;
RT   "Structural and membrane binding analysis of the Phox homology domain
RT   of phosphoinositide 3-kinase-C2alpha.";
RL   J. Biol. Chem. 281:39396-39406(2006).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 1421-1532.
RA   Parkinson G.N., Vines D., Driscoll P.C., Djordjevic S.;
RT   "Ligand-binding specificity of PI3kinase C2alpha PX domain.";
RL   Submitted (OCT-2006) to the PDB data bank.
CC   -!- FUNCTION: Generates phosphatidylinositol 3-phosphate (PtdIns3P)
CC       and phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P2) that act
CC       as second messengers. Has a role in several intracellular
CC       trafficking events. Functions in insulin signaling and secretion.
CC       Required for translocation of the glucose transporter SLC2A4/GLUT4
CC       to the plasma membrane and glucose uptake in response to insulin-
CC       mediated RHOQ activation. Regulates insulin secretion through two
CC       different mechanisms: involved in glucose-induced insulin
CC       secretion downstream of insulin receptor in a pathway that
CC       involves AKT1 activation and TBC1D4/AS160 phosphorylation, and
CC       participates in the late step of insulin granule exocytosis
CC       probably in insulin granule fusion. Synthesizes PtdIns3P in
CC       response to insulin signaling. Functions in clathrin-coated
CC       endocytic vesicle formation and distribution. Regulates dynamin-
CC       independent endocytosis, probably by recruiting EEA1 to
CC       internalizing vesicles. In neurosecretory cells synthesizes
CC       PtdIns3P on large dense core vesicles. Participates in calcium
CC       induced contraction of vascular smooth muscle by regulating myosin
CC       light chain (MLC) phosphorylation through a mechanism involving
CC       Rho kinase-dependent phosphorylation of the MLCP-regulatory
CC       subunit MYPT1. May play a role in the EGF signaling cascade. May
CC       be involved in mitosis and UV-induced damage response. Required
CC       for maintenance of normal renal structure and function by
CC       supporting normal podocyte function. {ECO:0000269|PubMed:10766823,
CC       ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11239472,
CC       ECO:0000269|PubMed:12719431, ECO:0000269|PubMed:16215232,
CC       ECO:0000269|PubMed:21081650, ECO:0000269|PubMed:9337861}.
CC   -!- CATALYTIC ACTIVITY: ATP + 1-phosphatidyl-1D-myo-inositol 4-
CC       phosphate = ADP + 1-phosphatidyl-1D-myo-inositol 3,4-bisphosphate.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000269|PubMed:10805725,
CC         ECO:0000269|PubMed:9337861};
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:10805725,
CC         ECO:0000269|PubMed:9337861};
CC       Note=Ca(2+) or Mg(2+). Mn(2+) cannot be used.
CC       {ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:9337861};
CC   -!- ENZYME REGULATION: Activated by insulin (By similarity). Only
CC       slightly inhibited by wortmannin and LY294002. Activated by
CC       clathrin. {ECO:0000250, ECO:0000269|PubMed:10766823,
CC       ECO:0000269|PubMed:11239472, ECO:0000269|PubMed:9337861}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=122 uM for PtdIns (in the absence of phosphatidylserine)
CC         {ECO:0000269|PubMed:9337861};
CC         KM=64 uM for PtdIns (in the presence of phosphatidylserine)
CC         {ECO:0000269|PubMed:9337861};
CC         KM=25 uM for PtdIns4P (in the presence of phosphatidylserine)
CC         {ECO:0000269|PubMed:9337861};
CC         KM=15 uM for ATP (with PtdIns as substrate) (in the absence of
CC         phosphatidylserine) {ECO:0000269|PubMed:9337861};
CC         KM=32 uM for ATP (with PtdIns as substrate) (in the presence of
CC         phosphatidylserine) {ECO:0000269|PubMed:9337861};
CC         KM=54 uM for ATP (with PtdIns4P as substrate) (in the presence
CC         of phosphatidylserine) {ECO:0000269|PubMed:9337861};
CC         Vmax=990 pmol/min/mg enzyme with PtdIns as substrate (in the
CC         absence of phosphatidylserine) {ECO:0000269|PubMed:9337861};
CC         Vmax=200 pmol/min/mg enzyme with PtdIns as substrate (in the
CC         presence of phosphatidylserine) {ECO:0000269|PubMed:9337861};
CC         Vmax=240 pmol/min/mg enzyme with PtdIns4P as substrate (in the
CC         presence of phosphatidylserine) {ECO:0000269|PubMed:9337861};
CC         Vmax=6800 pmol/min/mg enzyme toward ATP with PtdIns as substrate
CC         (in the absence of phosphatidylserine)
CC         {ECO:0000269|PubMed:9337861};
CC         Vmax=805 pmol/min/mg enzyme toward ATP with PtdIns as substrate
CC         (in the presence of phosphatidylserine)
CC         {ECO:0000269|PubMed:9337861};
CC         Vmax=880 pmol/min/mg enzyme toward ATP with PtdIns4P as
CC         substrate (in the presence of phosphatidylserine)
CC         {ECO:0000269|PubMed:9337861};
CC         Note=In the absence of the carrier phosphatidylserine, enzymatic
CC         kinetics toward PtdIns4P are non-linear.;
CC   -!- SUBUNIT: Part of a complex with ERBB2 and EGFR. Interacts with
CC       clathrin trimers. {ECO:0000269|PubMed:10805725,
CC       ECO:0000269|PubMed:11239472, ECO:0000269|PubMed:16215232}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10766823,
CC       ECO:0000269|PubMed:11239472, ECO:0000269|PubMed:17038310}. Golgi
CC       apparatus {ECO:0000269|PubMed:10766823,
CC       ECO:0000269|PubMed:11239472}. Cytoplasmic vesicle, clathrin-coated
CC       vesicle {ECO:0000269|PubMed:10766823,
CC       ECO:0000269|PubMed:11239472}. Nucleus
CC       {ECO:0000269|PubMed:11606566}. Cytoplasm
CC       {ECO:0000269|PubMed:11606566, ECO:0000269|PubMed:14563213}.
CC       Note=Inserts preferentially into membranes containing
CC       PtdIns(4,5)P2 (PubMed:17038310). Associated with RNA-containing
CC       structures (PubMed:11606566). {ECO:0000269|PubMed:11606566,
CC       ECO:0000269|PubMed:17038310}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O00443-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O00443-2; Sequence=VSP_056158;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in columnar and transitional
CC       epithelia, mononuclear cells, smooth muscle cells, and endothelial
CC       cells lining capillaries and small venules (at protein level).
CC       Ubiquitously expressed, with highest levels in heart, placenta and
CC       ovary, and lowest levels in the kidney. Detected at low levels in
CC       islets of Langerhans from type 2 diabetes mellitus individuals.
CC       {ECO:0000269|PubMed:14563213, ECO:0000269|PubMed:21127054,
CC       ECO:0000269|PubMed:9337861}.
CC   -!- PTM: Phosphorylated upon insulin stimulation; which may lead to
CC       enzyme activation (By similarity). Phosphorylated on Ser-259
CC       during mitosis and upon UV irradiation; which does not change
CC       enzymatic activity but leads to proteasomal degradation. Ser-259
CC       phosphorylation may be mediated by CDK1 or JNK, depending on the
CC       physiological state of the cell. {ECO:0000250,
CC       ECO:0000269|PubMed:11606566, ECO:0000269|PubMed:12719431}.
CC   -!- SIMILARITY: Belongs to the PI3/PI4-kinase family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00879, ECO:0000255|PROSITE-
CC       ProRule:PRU00880}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y13367; CAA73797.1; -; mRNA.
DR   EMBL; AK304262; BAG65126.1; -; mRNA.
DR   EMBL; EU332862; ABY87551.1; -; Genomic_DNA.
DR   EMBL; AC107956; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC116533; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC126389; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471064; EAW68447.1; -; Genomic_DNA.
DR   EMBL; BC113658; AAI13659.1; -; mRNA.
DR   CCDS; CCDS7824.1; -. [O00443-1]
DR   PIR; PC4345; PC4345.
DR   RefSeq; NP_001308307.1; NM_001321378.1. [O00443-1]
DR   RefSeq; NP_002636.2; NM_002645.3. [O00443-1]
DR   RefSeq; XP_016873413.1; XM_017017924.1. [O00443-1]
DR   UniGene; Hs.175343; -.
DR   UniGene; Hs.736397; -.
DR   PDB; 2AR5; X-ray; 1.80 A; A=1421-1532.
DR   PDB; 2IWL; X-ray; 2.60 A; X=1405-1544.
DR   PDB; 2REA; X-ray; 2.50 A; A=1421-1532.
DR   PDB; 2RED; X-ray; 2.10 A; A=1421-1532.
DR   PDBsum; 2AR5; -.
DR   PDBsum; 2IWL; -.
DR   PDBsum; 2REA; -.
DR   PDBsum; 2RED; -.
DR   ProteinModelPortal; O00443; -.
DR   SMR; O00443; -.
DR   BioGrid; 111304; 62.
DR   DIP; DIP-33727N; -.
DR   IntAct; O00443; 43.
DR   MINT; MINT-2794824; -.
DR   STRING; 9606.ENSP00000265970; -.
DR   BindingDB; O00443; -.
DR   ChEMBL; CHEMBL1075102; -.
DR   GuidetoPHARMACOLOGY; 2150; -.
DR   SwissLipids; SLP:000000892; -.
DR   iPTMnet; O00443; -.
DR   PhosphoSitePlus; O00443; -.
DR   BioMuta; PIK3C2A; -.
DR   EPD; O00443; -.
DR   MaxQB; O00443; -.
DR   PaxDb; O00443; -.
DR   PeptideAtlas; O00443; -.
DR   PRIDE; O00443; -.
DR   DNASU; 5286; -.
DR   Ensembl; ENST00000265970; ENSP00000265970; ENSG00000011405. [O00443-1]
DR   GeneID; 5286; -.
DR   KEGG; hsa:5286; -.
DR   UCSC; uc001mmq.6; human. [O00443-1]
DR   CTD; 5286; -.
DR   DisGeNET; 5286; -.
DR   GeneCards; PIK3C2A; -.
DR   HGNC; HGNC:8971; PIK3C2A.
DR   HPA; HPA037641; -.
DR   HPA; HPA037642; -.
DR   MIM; 603601; gene.
DR   neXtProt; NX_O00443; -.
DR   OpenTargets; ENSG00000011405; -.
DR   PharmGKB; PA33304; -.
DR   eggNOG; KOG0905; Eukaryota.
DR   eggNOG; COG5032; LUCA.
DR   GeneTree; ENSGT00760000119110; -.
DR   HOGENOM; HOG000006920; -.
DR   HOVERGEN; HBG082099; -.
DR   InParanoid; O00443; -.
DR   KO; K00923; -.
DR   OMA; TIQRGQW; -.
DR   OrthoDB; EOG091G00FC; -.
DR   PhylomeDB; O00443; -.
DR   TreeFam; TF102031; -.
DR   BioCyc; MetaCyc:HS00315-MONOMER; -.
DR   BRENDA; 2.7.1.154; 2681.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-HSA-1660514; Synthesis of PIPs at the Golgi membrane.
DR   Reactome; R-HSA-1660516; Synthesis of PIPs at the early endosome membrane.
DR   Reactome; R-HSA-1660517; Synthesis of PIPs at the late endosome membrane.
DR   Reactome; R-HSA-432722; Golgi Associated Vesicle Biogenesis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   SABIO-RK; O00443; -.
DR   SIGNOR; O00443; -.
DR   ChiTaRS; PIK3C2A; human.
DR   EvolutionaryTrace; O00443; -.
DR   GeneWiki; PIK3C2A; -.
DR   GenomeRNAi; 5286; -.
DR   PRO; PR:O00443; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000011405; -.
DR   CleanEx; HS_PIK3C2A; -.
DR   ExpressionAtlas; O00443; baseline and differential.
DR   Genevisible; O00443; HS.
DR   GO; GO:0030136; C:clathrin-coated vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0005942; C:phosphatidylinositol 3-kinase complex; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031982; C:vesicle; IDA:UniProtKB.
DR   GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; TAS:ProtInc.
DR   GO; GO:0035005; F:1-phosphatidylinositol-4-phosphate 3-kinase activity; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0035004; F:phosphatidylinositol 3-kinase activity; TAS:UniProtKB.
DR   GO; GO:0035091; F:phosphatidylinositol binding; IEA:InterPro.
DR   GO; GO:0048268; P:clathrin coat assembly; TAS:UniProtKB.
DR   GO; GO:0006897; P:endocytosis; IMP:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0006887; P:exocytosis; TAS:UniProtKB.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IEA:InterPro.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0014829; P:vascular smooth muscle contraction; TAS:UniProtKB.
DR   Gene3D; 1.10.1070.11; -; 1.
DR   Gene3D; 2.60.40.150; -; 2.
DR   Gene3D; 3.30.1520.10; -; 1.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR001683; Phox.
DR   InterPro; IPR000403; PI3/4_kinase_cat_dom.
DR   InterPro; IPR018936; PI3/4_kinase_CS.
DR   InterPro; IPR002420; PI3K_C2_dom.
DR   InterPro; IPR000341; PI3K_Ras-bd_dom.
DR   InterPro; IPR015433; PI_Kinase.
DR   InterPro; IPR001263; PInositide-3_kin_accessory_dom.
DR   InterPro; IPR029071; Ubiquitin-rel_dom.
DR   PANTHER; PTHR10048; PTHR10048; 1.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00454; PI3_PI4_kinase; 1.
DR   Pfam; PF00792; PI3K_C2; 1.
DR   Pfam; PF00794; PI3K_rbd; 1.
DR   Pfam; PF00613; PI3Ka; 1.
DR   Pfam; PF00787; PX; 1.
DR   SMART; SM00239; C2; 2.
DR   SMART; SM00142; PI3K_C2; 1.
DR   SMART; SM00144; PI3K_rbd; 1.
DR   SMART; SM00145; PI3Ka; 1.
DR   SMART; SM00146; PI3Kc; 1.
DR   SMART; SM00312; PX; 1.
DR   SUPFAM; SSF48371; SSF48371; 1.
DR   SUPFAM; SSF49562; SSF49562; 2.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF64268; SSF64268; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS00915; PI3_4_KINASE_1; 1.
DR   PROSITE; PS00916; PI3_4_KINASE_2; 1.
DR   PROSITE; PS50290; PI3_4_KINASE_3; 1.
DR   PROSITE; PS51547; PI3K_C2; 1.
DR   PROSITE; PS51546; PI3K_RBD; 1.
DR   PROSITE; PS51545; PIK_HELICAL; 1.
DR   PROSITE; PS50195; PX; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Cell membrane; Complete proteome; Cytoplasm; Cytoplasmic vesicle;
KW   Endocytosis; Exocytosis; Golgi apparatus; Kinase; Membrane;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Transferase.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330}.
FT   CHAIN         2   1686       Phosphatidylinositol 4-phosphate 3-kinase
FT                                C2 domain-containing subunit alpha.
FT                                /FTId=PRO_0000088795.
FT   DOMAIN      421    509       PI3K-RBD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00879}.
FT   DOMAIN      682    841       C2 PI3K-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00041, ECO:0000255|PROSITE-
FT                                ProRule:PRU00880}.
FT   DOMAIN      861   1037       PIK helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00878}.
FT   DOMAIN     1133   1397       PI3K/PI4K. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00269}.
FT   DOMAIN     1422   1538       PX. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00147}.
FT   DOMAIN     1559   1662       C2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00041}.
FT   REGION        2    142       Interaction with clathrin; sufficient to
FT                                induce clathrin assemby.
FT   REGION     1488   1493       Interaction with PtdIns(4,5)P2-containing
FT                                membranes.
FT   MOTIF      1608   1619       Nuclear localization signal.
FT                                {ECO:0000269|PubMed:11606566}.
FT   SITE        244    244       Not phosphorylated.
FT                                {ECO:0000269|PubMed:12719431}.
FT   SITE        249    249       Not phosphorylated.
FT                                {ECO:0000269|PubMed:12719431}.
FT   SITE        251    251       Not phosphorylated.
FT                                {ECO:0000269|PubMed:12719431}.
FT   SITE        254    254       Not phosphorylated.
FT                                {ECO:0000269|PubMed:12719431}.
FT   SITE        262    262       Not phosphorylated.
FT                                {ECO:0000269|PubMed:12719431}.
FT   SITE        266    266       Not phosphorylated.
FT                                {ECO:0000269|PubMed:12719431}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES      60     60       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     108    108       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     259    259       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:12719431}.
FT   MOD_RES     327    327       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     338    338       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     630    630       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1281   1281       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1553   1553       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ     484   1686       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056158.
FT   VARIANT    1415   1415       T -> A (in dbSNP:rs11604561).
FT                                /FTId=VAR_023333.
FT   MUTAGEN     103    107       LLLDD->AAAAA: Reduces clathrin binding.
FT                                {ECO:0000269|PubMed:11239472}.
FT   MUTAGEN     254    254       S->A: No effect on phosphorylation in
FT                                vitro. {ECO:0000269|PubMed:12719431}.
FT   MUTAGEN     259    259       S->A,D,E: Abolishes phosphorylation, no
FT                                change in activity.
FT                                {ECO:0000269|PubMed:12719431}.
FT   MUTAGEN     259    259       S->A: Protects from proteolysis.
FT                                {ECO:0000269|PubMed:12719431}.
FT   MUTAGEN     262    262       S->A: No effect on phosphorylation in
FT                                vitro. {ECO:0000269|PubMed:12719431}.
FT   MUTAGEN     266    266       S->A: No effect on phosphorylation in
FT                                vitro. {ECO:0000269|PubMed:12719431}.
FT   MUTAGEN    1250   1250       D->A: Abolishes lipid kinase activity.
FT                                Affects clathrin distribution when
FT                                combined with a truncation encompassing
FT                                the region of clathrin interaction.
FT                                {ECO:0000269|PubMed:16215232}.
FT   MUTAGEN    1488   1488       R->A: Reduces affinity for PtdIns(4,5)P2-
FT                                containing membranes 7-fold.
FT                                {ECO:0000269|PubMed:17038310}.
FT   MUTAGEN    1490   1490       V->A: Reduces affinity for PtdIns(4,5)P2-
FT                                containing membranes 7-fold.
FT                                {ECO:0000269|PubMed:17038310}.
FT   MUTAGEN    1491   1491       L->A: Reduces affinity for PtdIns(4,5)P2-
FT                                containing membranes 5-fold.
FT                                {ECO:0000269|PubMed:17038310}.
FT   MUTAGEN    1493   1493       R->A: Reduces affinity for PtdIns(4,5)P2-
FT                                containing membranes 23-fold.
FT                                {ECO:0000269|PubMed:17038310}.
FT   MUTAGEN    1503   1503       R->A: Abolishes interaction with
FT                                PtdIns(4,5)P2-containing membranes.
FT                                {ECO:0000269|PubMed:17038310}.
FT   CONFLICT      5      5       S -> F (in Ref. 1; CAA73797).
FT                                {ECO:0000305}.
FT   CONFLICT     15     15       S -> F (in Ref. 1; CAA73797).
FT                                {ECO:0000305}.
FT   CONFLICT    483    483       N -> K (in Ref. 2; BAG65126).
FT                                {ECO:0000305}.
FT   CONFLICT    796    796       F -> C (in Ref. 1; CAA73797).
FT                                {ECO:0000305}.
FT   CONFLICT    799    799       K -> R (in Ref. 1; CAA73797).
FT                                {ECO:0000305}.
FT   CONFLICT    922    922       V -> G (in Ref. 1; CAA73797).
FT                                {ECO:0000305}.
FT   CONFLICT   1129   1129       M -> L (in Ref. 1; CAA73797).
FT                                {ECO:0000305}.
FT   CONFLICT   1450   1450       R -> W (in Ref. 1; CAA73797).
FT                                {ECO:0000305}.
FT   CONFLICT   1464   1464       D -> V (in Ref. 1; CAA73797).
FT                                {ECO:0000305}.
FT   HELIX      1418   1421       {ECO:0000244|PDB:2IWL}.
FT   STRAND     1422   1433       {ECO:0000244|PDB:2AR5}.
FT   STRAND     1437   1440       {ECO:0000244|PDB:2AR5}.
FT   STRAND     1443   1450       {ECO:0000244|PDB:2AR5}.
FT   STRAND     1457   1462       {ECO:0000244|PDB:2AR5}.
FT   HELIX      1463   1476       {ECO:0000244|PDB:2AR5}.
FT   HELIX      1479   1481       {ECO:0000244|PDB:2AR5}.
FT   STRAND     1491   1495       {ECO:0000244|PDB:2AR5}.
FT   HELIX      1498   1515       {ECO:0000244|PDB:2AR5}.
FT   HELIX      1519   1522       {ECO:0000244|PDB:2AR5}.
FT   HELIX      1525   1530       {ECO:0000244|PDB:2AR5}.
FT   TURN       1535   1537       {ECO:0000244|PDB:2IWL}.
SQ   SEQUENCE   1686 AA;  190680 MW;  904AA5470F80DAC6 CRC64;
     MAQISSNSGF KECPSSHPEP TRAKDVDKEE ALQMEAEALA KLQKDRQVTD NQRGFELSSS
     TRKKAQVYNK QDYDLMVFPE SDSQKRALDI DVEKLTQAEL EKLLLDDSFE TKKTPVLPVT
     PILSPSFSAQ LYFRPTIQRG QWPPGLPGPS TYALPSIYPS TYSKQAAFQN GFNPRMPTFP
     STEPIYLSLP GQSPYFSYPL TPATPFHPQG SLPIYRPVVS TDMAKLFDKI ASTSEFLKNG
     KARTDLEITD SKVSNLQVSP KSEDISKFDW LDLDPLSKPK VDNVEVLDHE EEKNVSSLLA
     KDPWDAVLLE ERSTANCHLE RKVNGKSLSV ATVTRSQSLN IRTTQLAKAQ GHISQKDPNG
     TSSLPTGSSL LQEVEVQNEE MAAFCRSITK LKTKFPYTNH RTNPGYLLSP VTAQRNICGE
     NASVKVSIDI EGFQLPVTFT CDVSSTVEII IMQALCWVHD DLNQVDVGSY VLKVCGQEEV
     LQNNHCLGSH EHIQNCRKWD TEIRLQLLTF SAMCQNLART AEDDETPVDL NKHLYQIEKP
     CKEAMTRHPV EELLDSYHNQ VELALQIENQ HRAVDQVIKA VRKICSALDG VETLAITESV
     KKLKRAVNLP RSKTADVTSL FGGEDTSRSS TRGSLNPENP VQVSINQLTA AIYDLLRLHA
     NSGRSPTDCA QSSKSVKEAW TTTEQLQFTI FAAHGISSNW VSNYEKYYLI CSLSHNGKDL
     FKPIQSKKVG TYKNFFYLIK WDELIIFPIQ ISQLPLESVL HLTLFGILNQ SSGSSPDSNK
     QRKGPEALGK VSLPLFDFKR FLTCGTKLLY LWTSSHTNSV PGTVTKKGYV MERIVLQVDF
     PSPAFDIIYT TPQVDRSIIQ QHNLETLEND IKGKLLDILH KDSSLGLSKE DKAFLWEKRY
     YCFKHPNCLP KILASAPNWK WVNLAKTYSL LHQWPALYPL IALELLDSKF ADQEVRSLAV
     TWIEAISDDE LTDLLPQFVQ ALKYEIYLNS SLVQFLLSRA LGNIQIAHNL YWLLKDALHD
     VQFSTRYEHV LGALLSVGGK RLREELLKQT KLVQLLGGVA EKVRQASGSA RQVVLQRSME
     RVQSFFQKNK CRLPLKPSLV AKELNIKSCS FFSSNAVPLK VTMVNADPMG EEINVMFKVG
     EDLRQDMLAL QMIKIMDKIW LKEGLDLRMV IFKCLSTGRD RGMVELVPAS DTLRKIQVEY
     GVTGSFKDKP LAEWLRKYNP SEEEYEKASE NFIYSCAGCC VATYVLGICD RHNDNIMLRS
     TGHMFHIDFG KFLGHAQMFG SFKRDRAPFV LTSDMAYVIN GGEKPTIRFQ LFVDLCCQAY
     NLIRKQTNLF LNLLSLMIPS GLPELTSIQD LKYVRDALQP QTTDAEATIF FTRLIESSLG
     SIATKFNFFI HNLAQLRFSG LPSNDEPILS FSPKTYSFRQ DGRIKEVSVF TYHKKYNPDK
     HYIYVVRILR EGQIEPSFVF RTFDEFQELH NKLSIIFPLW KLPGFPNRMV LGRTHIKDVA
     AKRKIELNSY LQSLMNASTD VAECDLVCTF FHPLLRDEKA EGIARSADAG SFSPTPGQIG
     GAVKLSISYR NGTLFIMVMH IKDLVTEDGA DPNPYVKTYL LPDNHKTSKR KTKISRKTRN
     PTFNEMLVYS GYSKETLRQR ELQLSVLSAE SLRENFFLGG VTLPLKDFNL SKETVKWYQL
     TAATYL
//
